Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
Authors
Keywords
Multiple sclerosis, ocrelizumab, rituximab, B-cell-depleting therapy, progressive MS, relapsing-remitting MS
Journal
Neurotherapeutics
Volume 14, Issue 4, Pages 835-841
Publisher
Springer Nature
Online
2017-07-11
DOI
10.1007/s13311-017-0557-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
- (2017) Daniel Ontaneda et al. LANCET
- Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients
- (2017) Juhan Lee et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple sclerosis: experimental models and reality
- (2016) Hans Lassmann et al. ACTA NEUROPATHOLOGICA
- Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy
- (2016) Wai-Kay Seto et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Improving testing for hepatitis B before treatment with rituximab
- (2016) Jessica K. Dyson et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity
- (2016) Erin E. Longbrake et al. JAMA Neurology
- Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
- (2016) Mika Komori et al. Annals of Clinical and Translational Neurology
- Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)
- (2015) P. S. Rommer et al. Journal of Neuroimmune Pharmacology
- Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
- (2015) Rui Li et al. Science Translational Medicine
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
- (2015) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
- (2014) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
- Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
- (2014) R. C. Dale et al. NEUROLOGY
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
- (2014) P. S. Sorensen et al. NEUROLOGY
- Management of Multiple Sclerosis During Pregnancy and the Reproductive Years
- (2014) Riley Bove et al. OBSTETRICS AND GYNECOLOGY
- Disease Activity Free Status
- (2014) Carolyn J. Bevan et al. JAMA Neurology
- Specific peripheral B cell tolerance defects in patients with multiple sclerosis
- (2013) Tuure Kinnunen et al. JOURNAL OF CLINICAL INVESTIGATION
- Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude
- (2013) R. Dobson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- B cells and antibodies in multiple sclerosis pathogenesis and therapy
- (2012) Markus Krumbholz et al. Nature Reviews Neurology
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
- (2011) David B. Clifford ARCHIVES OF NEUROLOGY
- Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
- (2011) Owain W. Howell et al. BRAIN
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
- (2011) Stephen Sawcer et al. NATURE
- A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
- (2010) Roberta Magliozzi et al. ANNALS OF NEUROLOGY
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
- (2009) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities
- (2009) H. Tremlett et al. JOURNAL OF NEUROLOGY
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started